Eli Lilly retatrutide trials, access & market backdrop

Late July 2026 topline data from Phase III TRIUMPH‑2 and TRIUMPH‑3 showed retatrutide induced up to 22.6 % weight loss in severely obese adults with cardiovascular disease, alongside improvements in glycaemic control, lipids, blood pressure and inflammatory markers. The most common adverse events were gastrointestinal. On 4 August 2026 Lilly announced a compassionate‑use program, initially limited to patients with serious unmet medical needs and later broadened to allow more severely obese adults in the United States to apply while FDA review continues, with a planned biologics‑license submission in early 2027.

The early‑access rollout comes as Lilly’s GLP‑1 portfolio, especially Mounjaro, experiences rapid market expansion. Global Mounjaro sales doubled to $18.6 billion in the first half of 2026 and the company extended its LillyDirect home‑delivery service to all UK private weight‑management pharmacies. Analysts note that the growing demand for GLP‑1 agents has sparked safety discussions, including a large observational study reporting new side effects such as hair loss and mixed public reactions. Despite heightened market activity, Lilly remains focused on completing manufacturing and quality‑control verifications before filing for FDA approval in 2027.